Söndag 11 Maj | 23:05:39 Europe / Stockholm

Kalender

Est. tid*
2026-02-19 08:00 Bokslutskommuniké 2025
2025-10-31 08:00 Kvartalsrapport 2025-Q3
2025-08-14 08:00 Kvartalsrapport 2025-Q2
2025-05-16 N/A X-dag ordinarie utdelning IMP A 0.00 SEK
2025-05-15 N/A Årsstämma
2025-05-09 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning IMP A 0.00 SEK
2024-05-22 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning IMP A 0.00 SEK
2023-05-25 - Årsstämma
2023-05-12 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-15 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning IMP A 0.00 SEK
2022-05-11 - Kvartalsrapport 2022-Q1
2022-05-10 - Årsstämma
2022-02-18 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-09-17 - Extra Bolagsstämma 2021
2021-08-24 - Kvartalsrapport 2021-Q2
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-19 - X-dag ordinarie utdelning IMP A 0.00 SEK
2021-04-16 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-18 - Kvartalsrapport 2020-Q3

Beskrivning

LandLiechtenstein
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Implantica är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar implanterbara medicinska instrument, som vidare används för behandling av sjukdomar som berör matstrupen. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster, särskilt inriktat mot eHälsa. Verksamheten drivs globalt med störst närvaro inom Nordamerika samt Europa.
2023-06-29 08:00:00

Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces that the first RefluxStop™ procedures have been performed in another leading reflux center of excellence in the Puglia region in Italy - IRCCS Saverio De Bellis - the fourth center of excellence to start in Italy within a couple of months.

Three RefluxStop procedures to treat gastroesophageal reflux disease (GERD) were successfully performed by Dr. Leonardo Vincenti, Director of the Department of Surgical Sciences at IRCCS Saverio De Bellis.

"This minimally invasive procedure restores the normal anatomy of the esophageal-gastric junction so that it can prevent reflux," said Dr. Vincenti. "Unlike traditional surgical interventions, RefluxStop does not have side effects such as difficulty swallowing the food bolus, gas bloating, etc. "

IRCCS Saverio De Bellis, Castellana Grotte, is a nationally recognized specialized hospital for gastroenterology as part of the IRCCS network of hospitals.

In recognition of the availability of a new treatment option for acid reflux disease in the Puglia region, esteemed gastroenterologists from nearby centers and universities attended Dr. Vincenti's speech on the same day of surgery to learn more about the RefluxStop procedure. Several local media representatives announced and commented about RefluxStop procedures on their respective media outlets (https://norbaonline.it/2023/05/30/castellana-grotte-nuova-tecnica-anti-reflusso-al-de-bellis/) leading to high interest from patients and many inquiries about the procedure.

"We are glad and honored to work with Dr. Vincenti, a leading anti-reflux expert in Italy. Implantica is currently only focusing on centers of excellence. De Bellis is a well-recognized center of excellence for reflux and will play an important role in making RefluxStop treatment available to a broader patient population in Italy. We thank Dr. Vincenti for his great support and partnership to help advance care for reflux patients with RefluxStop therapy," said Dr. Peter Forsell, CEO of Implantica.

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on June 29, 2023, at 08:00 a.m. (CEST).

About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop™

RefluxStop is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions.  Existing surgical procedures and devices are focused on the Lower Esophageal Sphincter (LES) with a principal assumption that the LES is weak and or improperly functioning thereby not closing properly. These methods encircle the food passageway to support the LES's closing sphincter and are commonly  associated with side effects such as swallowing difficulties, inability to belch and vomit and gas bloating.In contrast, the RefluxStop device addresses acid reflux without affecting the food passageway.

The RefluxStop mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.

Newsroom
https://www.implantica.com/media/media-kit

https://norbaonline.it/2023/05/30/castellana-grotte-nuova-tecnica-anti-reflusso-al-de-bellis/

https://www.sanita.puglia.it/web/debellis

Community

https://www.linkedin.com/implantica

https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart
VP Marketing & Advocacy

M: +1 925-381-4581
juanita.eberhart@implantica.com